Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice

Carolyn Tallon, Benjamin J. Bell, Anjali Sharma, Arindom Pal, Medhinee M. Malvankar, Ajit G. Thomas, Seung Wan Yoo, Kristen Hollinger, Kaleem Coleman, Elizabeth L. Wilkinson, Sujatha Kannan, Norman J. Haughey, Rangaramanujam M. Kannan, Rana Rais, Barbara S. Slusher

Research output: Contribution to journalArticlepeer-review

Abstract

Alzheimer’s disease (AD) is characterized by the progressive accumulation of amyloid-β and hyperphosphorylated tau (pTau), which can spread throughout the brain via extracellular vesicles (EVs). Membrane ceramide enrichment regulated by the enzyme neutral sphingomyelinase 2 (nSMase2) is a critical component of at least one EV biogenesis pathway. Our group recently identified 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP), the most potent (30 nM) and selective inhibitor of nSMase2 reported to date. However, DPTIP exhibits poor oral pharmacokinetics (PK), modest brain penetration, and rapid clearance, limiting its clinical translation. To enhance its PK properties, we conjugated DPTIP to a hydroxyl-PAMAM dendrimer delivery system, creating dendrimer-DPTIP (D-DPTIP). In an acute brain injury model, orally administered D-DPTIP significantly reduced the intra-striatal IL-1β-induced increase in plasma EVs up to 72 h post-dose, while oral DPTIP had a limited effect. In a mouse tau propagation model, where a mutant hTau (P301L/S320F) containing adeno-associated virus was unilaterally seeded into the hippocampus, oral D-DPTIP (dosed 3× weekly) significantly inhibited brain nSMase2 activity and blocked the spread of pTau to the contralateral hippocampus. These data demonstrate that dendrimer conjugation of DPTIP improves its PK properties, resulting in significant inhibition of EV propagation of pTau in mice. Dendrimer-based delivery of DPTIP has the potential to be an exciting new therapeutic for AD.

Original languageEnglish (US)
Article number2066
JournalPharmaceutics
Volume14
Issue number10
DOIs
StatePublished - Oct 2022

Keywords

  • Alzheimer’s disease
  • DPTIP
  • PDDC
  • ceramide
  • dendrimer
  • extracellular vesicles
  • neutral sphingomyelinase 2
  • tau

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice'. Together they form a unique fingerprint.

Cite this